AR054021A1 - Derivados de ciclopentapiridina y tetrahidroquinolina - Google Patents
Derivados de ciclopentapiridina y tetrahidroquinolinaInfo
- Publication number
- AR054021A1 AR054021A1 ARP060101218A ARP060101218A AR054021A1 AR 054021 A1 AR054021 A1 AR 054021A1 AR P060101218 A ARP060101218 A AR P060101218A AR P060101218 A ARP060101218 A AR P060101218A AR 054021 A1 AR054021 A1 AR 054021A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- membered
- group
- heteroatoms independently
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
En este documento se describen compuestos 6,7-dihidro-5H-ciclopenta[b]piridina y 5,6,7,8-tetrahidroquinolina, incluyendo sales, hidratos y solvatos de los mismos, que actuan como ligandos del receptor 5-Ht2 y sus usos ene el tratamiento de enfermedades relacionadas con la activacion de los receptores 5-HT2c. Reivindicacion 1: Un compuesto de la formula (1) en la que m es 1 o 2; n es 0 o 1; L es -CHR0a-, donde R0a es hidrogeno o alquilo (C1-C4); R2 es hidrogeno o metilo; R3 se selecciona entre el grupo constituido por H, Cl, Br, F, CH3 y CN; R1 es (a) un grupo de la formula (2) donde (i) cada uno de p, r y s es independientemente 0 o 1, y cada uno de R1a, R1b y R1c se selecciona independientemente entre el grupo constituido por F, Cl, Br, I, ciano, -CH2-CN, -NH2, -OH, alquilo (C1-C6), alcoxi (C1-6), alquil (C1-C4) fluoro-sustituido, alcoxi (C1-C4), fluoro sustituido, alquil(C1-C4)-tio fluoro-sustituido, -NH-C(O)-alquilo (C1-C4),-C(O)-alquilo (C1-C4), -C(O)- O-alquilo (C1-C4), -C(O)-NH2, -C(O)-NH-alquilo (C1-C4), un anillo carbocíclico de 3 a 6 miembros y fenilo sustituido con F, CL, Br o I; (ii) cada uno de p y r es 0 o 1, s es 1, cada uno de R1b se selecciona independientemente entre F, Cl, Br, I, ciano, -NH2, -C(O)-alquilo (C1-4), alquilo (C1-6), alcoxi (C1-C6), alquil (C1-C4)-tio, alquilo (C1-C4) fluoro sustituido, alcoxi (C1-4) fluoro sustituido o alquil (C1-4)-tio fluoro-sustituido, y (R1c)s está unido a un átomo de carbono adyacente del anillo distinto del carbono mediante el cual el grupo de formula 1 A se une al resto de la molécula y (R1c)s tomado junto con los dos carbonos a los que está unido forma un anillo seleccionado entre el grupo constituido por: un anillo carbocíclico de 5 a 6 miembros que contiene opcionalmente un grupo ceto, un anillo heterocíclico de 5 a 6 miembros que contiene 1 a 2 heteroátomos seleccionados independientemente entre O, S, o N, y que contiene opcionalmente un grupo ceto, un anillo aromático de 6 miembros, y un anillo heteroaromático de 5 a 6 miembros que contiene de 1 a 2 heteroátomos seleccionados independientemente entre O, S o N, donde dicho anillo carbocíclico, dicho anillo heterocíclico, dicho anillo aromático y dicho anillo heteroaromático están opcionalmente sustituidos con 1 a 2 sustituyentes seleccionados entre el grupo constituido por alquil (C1-C4), ciano, acetilo, F, Cl, Br, I fenilamino, alquilo (C1-C4)-amino, un anillo heterocíclico de 5 a 6 miembros que contiene de 1 a 3 heteroátomos seleccionados independientemente entre N, O y S que está opcionalmente sustituido con 1 a 3 sustituyentes seleccionados entre alquilo (C1-C4) y un anillo heteroarilo de 5 a 6 miembros que contiene de 1 a 3 heteroátomos seleccionados independientemente entre N, O y S y que está opcionalmente sustituido con 1 a 3 sustituyentes seleccionados entre alquilo (C1-C4); o (iii) cada uno de p y r es 0, s es 1, y R1c se selecciona independientemente entre el grupo constituido por fenilo, fenoxi opcionalmente sustituido con F, Cl, Br o I; bencilo, benciloxi, -NH-alquilo (C1-C4), -N[alquilo (C1-C4)]2, -CH2-NH-alquilo(C1-C4), -CH2-N[alquilo (C1-C4)]2, -NH(fenilo), -NH(heteroarilo de 5 a 6 miembros que contiene de 1 a 3 heteroátomos seleccionados independientemente entre O, N y S, que está opcionalmente sustituido con 1 a 3 grupos halo), -N(CH3)-SO2alquilo (C1-4),- NH-SO2alquilo (C1-C4), -NHC(O)NH2, -C(O)-N[alquilo (C1-C4)]2, -C(O)-(heterociclo de 5 a 6 miembros que contiene de 1 a 3 heteroátomos seleccionados independientemente entre O, N y S), -C(O)-NH(heterociclo de 5 a 6 miembros que contiene de 1 a 3 heteroátomos seleccionados independientemente entre O, N y S), -C(O)-(carbociclo de 5 a 6 miembros), - CH2-C(O)-O-alquilo (C1-C4), un anillo heterocíclico de 3 a 6 miembros que contiene de 1 a 3 heteroátomos seleccionados independientemente entre O, N o S, y un heteroarilo de 5 a6 miembros que contiene de 1 a 3 heteroátomos seleccionados independientemente entre O, N o S que está opcionalmente sustituido con de uno a tres sustituyentes seleccionados independientemente entre F, Cl, Br I y -CF3; (b) un heteroarilo de 5 a 6 miembros que contiene de 1 a 3 heteroátomos seleccionados independientemente entre O, S o N, donde dicho heteroarilo está opcionalmente condensado con un anillo carbocíclico de 5 a 6 miembros o un anillo aromático de 6 miembros y dicho heteroarilo está opcionalmente sustituido con 1 a 2 sustituyentes seleccionados independientemente entre el grupo constituido por ciano, F, Cl, Br, I, alquilo (C1-C4), alcoxi (C1-C4) y -C(O)-O alquilo (C1-C4); o una sal farmacéuticamente aceptable del mismo, o un solvato o hidrato de dicho compuesto o de dicha sal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66718405P | 2005-03-31 | 2005-03-31 | |
US76215906P | 2006-01-26 | 2006-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054021A1 true AR054021A1 (es) | 2007-05-30 |
Family
ID=36218589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060101218A AR054021A1 (es) | 2005-03-31 | 2006-03-29 | Derivados de ciclopentapiridina y tetrahidroquinolina |
Country Status (24)
Country | Link |
---|---|
US (1) | US7507732B2 (es) |
EP (1) | EP1869000A1 (es) |
JP (1) | JP4318744B2 (es) |
KR (1) | KR100894006B1 (es) |
AP (1) | AP2007004144A0 (es) |
AR (1) | AR054021A1 (es) |
AU (1) | AU2006228378A1 (es) |
BR (1) | BRPI0609268A2 (es) |
CA (1) | CA2602348C (es) |
CR (1) | CR9386A (es) |
DO (1) | DOP2006000076A (es) |
EA (1) | EA200701853A1 (es) |
GT (1) | GT200600128A (es) |
IL (1) | IL185492A0 (es) |
MA (1) | MA29354B1 (es) |
MX (1) | MX2007012082A (es) |
NL (1) | NL1031473C2 (es) |
NO (1) | NO20074368L (es) |
NZ (1) | NZ560917A (es) |
PE (1) | PE20061333A1 (es) |
TN (1) | TNSN07367A1 (es) |
TW (1) | TW200722423A (es) |
UY (1) | UY29446A1 (es) |
WO (1) | WO2006103511A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7638519B2 (en) | 2003-12-23 | 2009-12-29 | Myogen, Inc. | Compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease |
JPWO2006064780A1 (ja) * | 2004-12-14 | 2008-06-12 | 塩野義製薬株式会社 | 便秘治療剤 |
EP2727585A1 (en) | 2006-05-16 | 2014-05-07 | Takeda Pharmaceutical Company Limited | In-vivo screening method |
KR20090029299A (ko) * | 2006-07-14 | 2009-03-20 | 화이자 프로덕츠 인코포레이티드 | (7s)-7-[(5-플루오로-2-메틸-벤질)옥시]-2-[(2r)-2-메틸피페라진-1-일]-6,7-다이하이드로-5h-사이클로펜타[b]피리딘의 타르트레이트 염 |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
ATE477243T1 (de) * | 2006-12-07 | 2010-08-15 | Hoffmann La Roche | 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten |
EP2789338A3 (en) | 2007-11-15 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Condensed pyridine derivate and use thereof |
EP2262773A1 (en) | 2008-03-07 | 2010-12-22 | F. Hoffmann-La Roche AG | 2-aminoquinoline derivatives |
SG176464A1 (en) | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α7活化劑之用途 |
WO2011071136A1 (ja) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
US8674218B2 (en) | 2010-12-15 | 2014-03-18 | General Electric Company | Restraint system for an energy storage device |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
EP3733204A4 (en) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE |
CN110236526B (zh) * | 2019-06-28 | 2022-01-28 | 李秋 | 基于咀嚼吞咽动作及心电活动的摄食行为分析和检测方法 |
WO2024026423A1 (en) * | 2022-07-27 | 2024-02-01 | Black Diamond Therapeutics, Inc. | Substituted quinoline derivatives as pi3k inhibitors |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01211581A (ja) | 1988-02-18 | 1989-08-24 | Meiji Seika Kaisha Ltd | シクロペンテノピリジン誘導体および抗潰瘍剤 |
US4985352A (en) * | 1988-02-29 | 1991-01-15 | The Trustees Of Columbia University In The City Of New York | DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof |
US5019574A (en) | 1988-09-30 | 1991-05-28 | Chugai Seiyaku Kabushiki Kaisha | 3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function |
DK0385237T3 (da) | 1989-03-03 | 1994-07-25 | Dainippon Pharmaceutical Co | 2-(1-Piperazinyl)-4-phenylcycloalkanopyridinderivater, fremgangsmåde til fremstilling deraf og farmaceutisk præparat indeholdende dem |
JP2660086B2 (ja) | 1990-07-03 | 1997-10-08 | 明治製菓株式会社 | 脳及び心機能障害改善剤 |
JPH04103572A (ja) | 1990-08-20 | 1992-04-06 | Dainippon Pharmaceut Co Ltd | 4―フェニル―2―(1―ピペラジニル)ピリジン誘導体 |
EP0572863A1 (de) | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | ZNS Pyrazinoindole |
DE4326151A1 (de) * | 1993-08-04 | 1995-02-09 | Hoechst Ag | Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen |
TW334423B (en) | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
TW270114B (es) | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
US5698766A (en) * | 1995-04-05 | 1997-12-16 | The Regents Of The University Of California | Transgenic animal model for testing drugs for treating eating disorders and epilepsy |
TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
AU5343298A (en) | 1997-01-13 | 1998-08-03 | Yamanouchi Pharmaceutical Co., Ltd. | 5-ht2c receptor agonists and aminoalkylindazole derivatives |
DE69725113T2 (de) | 1997-02-25 | 2004-07-15 | Akzo Nobel N.V. | Azetidin- und Pyrrolidinderivate |
US6322738B1 (en) | 1997-07-24 | 2001-11-27 | Husky Injection Molding Systems Ltd. | Method of injection over-molding articles |
US6040448A (en) * | 1997-10-24 | 2000-03-21 | Neurogen Corporation | Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands |
CN1191248C (zh) | 1997-10-24 | 2005-03-02 | 纽罗根公司 | 作为多巴胺d 受体亚型配体的1-(2-萘基)和1-(2-氮杂萘基)-4-(1-苯基甲基)哌嗪 |
WO1999058490A2 (en) | 1998-05-08 | 1999-11-18 | Akzo Nobel N.V. | Novel aryl-hydro naphthalenal kanamines |
CA2341678C (en) | 1998-09-01 | 2009-10-13 | Bristol-Myers Squibb Company | Potassium channel inhibitors and method |
GB9819019D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
GB9819035D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Res Ltd | Chemical compounds VII |
GB9819020D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds III |
GB9819033D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds VI |
JP2000191533A (ja) | 1998-10-19 | 2000-07-11 | Eisai Co Ltd | 鎮痛剤 |
AU1738900A (en) | 1998-11-19 | 2000-06-05 | Nortran Pharmaceuticals Inc. | Serotonin ligands as pro-erectile compounds |
WO2000044737A1 (en) | 1999-01-27 | 2000-08-03 | Eli Lilly And Company | Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists |
NZ515786A (en) | 1999-05-21 | 2004-01-30 | Biovitrum Ab | Aryl compounds, their preparation and use in the preparation of medicaments for the treatment of serotonin-related disorders |
US6538087B2 (en) * | 2000-07-28 | 2003-03-25 | Promerus, Llc | Polymeric compositions for forming optical waveguides; optical waveguides formed therefrom; and methods for making same |
SE0004245D0 (sv) * | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
AU2426602A (en) | 2000-11-20 | 2002-05-27 | Biovitrum Ab | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor |
TWI245761B (en) | 2001-03-01 | 2005-12-21 | Telik Inc | Antagonists of MCP-1 function and methods of use thereof |
ATE348097T1 (de) | 2001-04-09 | 2007-01-15 | Chiron Corp | Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten |
US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
JP2006522814A (ja) * | 2003-04-11 | 2006-10-05 | タイゲン・バイオテクノロジー | アミノキノリン化合物 |
US7101881B2 (en) | 2003-06-11 | 2006-09-05 | Pfizer Inc | Tetrahydroquinolines |
TW200612918A (en) | 2004-07-29 | 2006-05-01 | Threshold Pharmaceuticals Inc | Lonidamine analogs |
-
2006
- 2006-03-21 CA CA2602348A patent/CA2602348C/en not_active Expired - Fee Related
- 2006-03-21 EP EP06710585A patent/EP1869000A1/en not_active Withdrawn
- 2006-03-21 JP JP2008503608A patent/JP4318744B2/ja not_active Expired - Fee Related
- 2006-03-21 EA EA200701853A patent/EA200701853A1/ru unknown
- 2006-03-21 AU AU2006228378A patent/AU2006228378A1/en not_active Abandoned
- 2006-03-21 NZ NZ560917A patent/NZ560917A/en not_active IP Right Cessation
- 2006-03-21 MX MX2007012082A patent/MX2007012082A/es active IP Right Grant
- 2006-03-21 KR KR1020077022374A patent/KR100894006B1/ko not_active IP Right Cessation
- 2006-03-21 BR BRPI0609268-3A patent/BRPI0609268A2/pt not_active IP Right Cessation
- 2006-03-21 WO PCT/IB2006/000655 patent/WO2006103511A1/en not_active Application Discontinuation
- 2006-03-21 AP AP2007004144A patent/AP2007004144A0/xx unknown
- 2006-03-28 PE PE2006000343A patent/PE20061333A1/es not_active Application Discontinuation
- 2006-03-29 AR ARP060101218A patent/AR054021A1/es unknown
- 2006-03-29 GT GT200600128A patent/GT200600128A/es unknown
- 2006-03-30 DO DO2006000076A patent/DOP2006000076A/es unknown
- 2006-03-30 NL NL1031473A patent/NL1031473C2/nl not_active IP Right Cessation
- 2006-03-30 UY UY29446A patent/UY29446A1/es not_active Application Discontinuation
- 2006-03-30 TW TW095111125A patent/TW200722423A/zh unknown
- 2006-03-31 US US11/395,327 patent/US7507732B2/en not_active Expired - Fee Related
-
2007
- 2007-08-23 IL IL185492A patent/IL185492A0/en unknown
- 2007-08-27 NO NO20074368A patent/NO20074368L/no not_active Application Discontinuation
- 2007-09-19 CR CR9386A patent/CR9386A/es not_active Application Discontinuation
- 2007-09-28 TN TNP2007000367A patent/TNSN07367A1/fr unknown
- 2007-09-28 MA MA30262A patent/MA29354B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
KR20070107183A (ko) | 2007-11-06 |
NO20074368L (no) | 2007-09-21 |
AP2007004144A0 (en) | 2007-08-31 |
NZ560917A (en) | 2011-01-28 |
GT200600128A (es) | 2007-03-29 |
CA2602348A1 (en) | 2006-10-05 |
JP2008534568A (ja) | 2008-08-28 |
NL1031473C2 (nl) | 2007-03-19 |
TW200722423A (en) | 2007-06-16 |
MA29354B1 (fr) | 2008-03-03 |
MX2007012082A (es) | 2007-11-20 |
JP4318744B2 (ja) | 2009-08-26 |
PE20061333A1 (es) | 2007-01-13 |
NL1031473A1 (nl) | 2006-10-03 |
UY29446A1 (es) | 2006-10-31 |
BRPI0609268A2 (pt) | 2010-03-09 |
DOP2006000076A (es) | 2006-11-30 |
KR100894006B1 (ko) | 2009-04-17 |
CA2602348C (en) | 2011-03-01 |
WO2006103511A1 (en) | 2006-10-05 |
CR9386A (es) | 2007-10-02 |
EA200701853A1 (ru) | 2008-08-29 |
EP1869000A1 (en) | 2007-12-26 |
US7507732B2 (en) | 2009-03-24 |
IL185492A0 (en) | 2008-01-06 |
AU2006228378A1 (en) | 2006-10-05 |
TNSN07367A1 (fr) | 2008-12-31 |
US20060247254A1 (en) | 2006-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054021A1 (es) | Derivados de ciclopentapiridina y tetrahidroquinolina | |
ES2509820T3 (es) | Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer | |
AR050281A1 (es) | Derivados de indol, indazol e indazolina. procesos de obtencion y composiciones farmaceuticas | |
ES2524119T3 (es) | Furazanobencimidazoles como profármacos para tratar enfermedades neoplásicas o autoinmunes | |
JP2007507551A5 (es) | ||
AR053415A1 (es) | Inhibidores dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procesos para la preparacion de los compuestos y de la composicion | |
AR061567A1 (es) | Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos | |
AR079497A1 (es) | Derivados fenilimidazol que comprenden un enlazante de etinileno como inhibidores de enzima pde10a | |
AR066043A1 (es) | Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1) | |
UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
ES2570628T3 (es) | Nuevas arilamidas con sustitución imidazol | |
AR050953A1 (es) | Compuestos de sulfonamida inhibidores de los receptores de cck1/cck2 duales | |
CO6270328A2 (es) | Derivados de pirrolo [2,3] pirimidina como inhibidores de proteinas quinasas b | |
PE20070829A1 (es) | Inhibidores cetp heterociclicos | |
AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
AR062209A1 (es) | Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos. | |
CL2008002654A1 (es) | Compuestos derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, bloqueadores de los canales hcn; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cardiopatias isquemicas, insuficiencias cardiacas tanto sistolicas como diastolicas, entre otras. | |
PE20061127A1 (es) | Derivados de propanosulfonamida que potencian el receptor de glutamato | |
PE20080835A1 (es) | Derivados novedosos de aminopiridina que tienen accion inhibidora selectiva sobre aurora a | |
AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
AR079498A1 (es) | Derivados de 2-arilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
AR079496A1 (es) | Derivados de aril triazol heteroaromaticos como inhibidores de enzima pde10a | |
AR066606A1 (es) | Compuestos de heteroarilamida pirimidona | |
PE20011115A1 (es) | Etanos tri-aril-sustituidos inhibidores de pde4 | |
BR0316020A (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar um distúrbio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |